CTP‐543 for the Treatment of Adults with Moderate to Severe Alopecia Areata

Last Updated:
05/09/2017
Status:
Recruiting
Country:
United States
Eligibility:
Age 18‐65; diagnosed with moderate to severe alopecia areata
Drug:
CTP‐543
Administration:
Oral
Sponsor: 
Concert Pharmaceuticals, Inc.

The purpose of this study is to determine if oral CTP‐543 is safe and effective for the treatment of adults with alopecia areata. Approximately 100 patients with moderate to severe alopecia areata may participate in this study at 13 trial sites. Read More.